Clinical Trial Results:
A Randomized, Double-blind, Two Treatment, Two Period, Chronic Dosing (4 weeks), Cross-Over, Multi-Center Pilot Study to Evaluate the Effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycopyrronium/Formoterol Fumarate on Specific Image-based Airway Volumes and Resistance in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Summary
|
|
EudraCT number |
2018-001704-10 |
Trial protocol |
NL BE |
Global end of trial date |
11 Nov 2019
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
10 Feb 2021
|
First version publication date |
27 Nov 2020
|
Other versions |
v1 |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
D5980C00019
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AstraZeneca AB
|
||
Sponsor organisation address |
Pepparedsleden 1, Molndal, Sweden,
|
||
Public contact |
Magnus Aurivillius, AstraZeneca AB, magnus.aurivillius@astrazeneca.com
|
||
Scientific contact |
Magnus Aurivillius, AstraZeneca AB, magnus.aurivillius@astrazeneca.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
16 Dec 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
11 Nov 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
11 Nov 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the effects of BGF MDI and GFF MDI on specific image-based airway volumes and resistance in subjects with moderate to severe COPD following chronic twice daily (BID) dosing after approximately 4 weeks of treatment.
|
||
Protection of trial subjects |
Ventolin HFA was provided throughout the study for subjects to take as needed for relief of symptoms.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
26 Feb 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 7
|
||
Country: Number of subjects enrolled |
Netherlands: 16
|
||
Worldwide total number of subjects |
23
|
||
EEA total number of subjects |
23
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
14
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
This study randomized 23 subjects at 4 study centers (1 center in Belgium and 3 centers in the Netherlands) from 26 February 2019 to 11 November 2019. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Subjects were randomized into 1 of 2 treatment sequences. Sequence 1 received BGF MDI in Period 1 followed by GFF MDI in Period 2. Sequence 2 received GFF MDI in Period 1 followed by BGF MDI in Period 2. | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||
Blinding used |
Double blind | ||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Carer, Data analyst, Assessor | ||||||||||||
Blinding implementation details |
All Subjects Randomized
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Overall Study | ||||||||||||
Arm description |
- | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Pressurised inhalation, suspension
|
||||||||||||
Routes of administration |
Inhalation use
|
||||||||||||
Dosage and administration details |
BGF MDI 320/14.4/9.6 μg
|
||||||||||||
Investigational medicinal product name |
Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Pressurised inhalation, suspension
|
||||||||||||
Routes of administration |
Inhalation use
|
||||||||||||
Dosage and administration details |
GFF MDI 14.4/9.6 μg
|
||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Study
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All Subjects Randomized | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
BGF MDI
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All Subjects Randomized
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
GFF MDI
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All Subjects Randomized
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Overall Study
|
||
Reporting group description |
- | ||
Subject analysis set title |
BGF MDI
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All Subjects Randomized
|
||
Subject analysis set title |
GFF MDI
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All Subjects Randomized
|
|
|||||||||||||
End point title |
Specific Image-based Airway Volume (siVaw) [1] | ||||||||||||
End point description |
Specific Image-based Airway Volume (siVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Day 29
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: According to the protocol, the primary analysis in this study was not a comparison between treatments, it was a comparison to baseline within each treatment. Therefore, no statistical analysis is included in this form as to only name a single treatment arm for each analysis generated validation errors. The estimates and confidence intervals for each comparison to baseline are however provided. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Specific Image-based Airway Resistance (siRaw) [2] | ||||||||||||
End point description |
Specific Image-based Airway Resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Day 29
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: According to the protocol, the primary analysis in this study was not a comparison between treatments, it was a comparison to baseline within each treatment. Therefore, no statistical analysis is included in this form as to only name a single treatment arm for each analysis generated validation errors. The estimates and confidence intervals for each comparison to baseline are however provided. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Image-based Airway Volume (iVaw) | ||||||||||||
End point description |
Image-based Airway Volume (iVaw) measured in mL. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Day 29
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Image-based Airway Resistance (iRaw) | ||||||||||||
End point description |
Image-based Airway Resistance (iRaw) measured in kPa∙s/L. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Day 29
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Forced Expiratory Volume in 1 Second (Post-dose FEV1) | ||||||||||||
End point description |
Change from baseline in Forced Expiratory Volume in One Second (Post-dose FEV1)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Day 29
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Image-based Functional Residual Capacity (FRC) | ||||||||||||
End point description |
Change from baseline in Functional Residual Capacity (FRC).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Day 29
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were collected from Visit 2 throughout the treatment period and including the follow-up period telephone call.
|
||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The Safety Population was defined as all subjects who were randomized to treatment and received at least one dose of study treatment and for whom any post-dose data were available. Serious adverse events were collected from Visit 2 throughout the treatment period and including the follow-up period telephone call.
|
||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||
Dictionary version |
22.1
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
BGF MDI
|
||||||||||||||||||||||||||||||
Reporting group description |
Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation | ||||||||||||||||||||||||||||||
Reporting group title |
GFF MDI
|
||||||||||||||||||||||||||||||
Reporting group description |
Glycopyrronium/Formoterol Fumarate Metered Dose Inhalation | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |